RecruitingPhase 2NCT03301038
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
Studying Autosomal recessive infantile hypercalcemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Philadelphia
- Principal Investigator
- Michael A Levine, MDChildren'sHospital of Philadelphia
- Intervention
- Rifampin(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 65 years · All sexes
- Timeline
- 2018 – 2030
Study locations (1)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03301038 on ClinicalTrials.govOther trials for Autosomal recessive infantile hypercalcemia
Additional recruiting or active studies for the same condition.
See all trials for Autosomal recessive infantile hypercalcemia →